Abstract 26P
Background
The aim of this work was to evaluate the association between body mass index (BMI) and clinical outcomes among Egyptian breast cancer patients.
Methods
We reviewed the file registry of 629 patients with operable breast cancer regarding age, sex, height, weight, family history of breast cancer, menopausal status, tumor characteristics, TNM classification, and treatment during the period from January 2006 to December 2012. In our analyses, obesity was defined as a BMI of ≥30 kg/m2. The primary objective was to estimate the effect of obesity on the clinical outcomes of breast cancer patients including DFS and OAS.
Results
A total of 629 patients with a mean age of 51.1 years. Stage III and Stage II presented 52% and 46.6% respectively. Overweight and obese patients represent 60.5% of all patient population. there was no association between tumor stage, grade or menopausal status and BMI. Patients with normal BMI showed a median survival of 95.3 months [ CI: 54.6,136.06]. This was significantly higher than overweight and obese patients (p = 0.001). Nearly one-third of patients (29.1%) with normal BMI experienced disease relapse compared to 32.8% for overweight and obese patients, however, this was statistically not significant (0.097).
Conclusions
According to the results of this retrospective study, Obesity is an independent prognostic factor for OS in patients with operable breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Minia University Hospital and Mansura University Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
124P - Prospective evaluation of pattern of care and quality of life in patients undergoing esophagectomy at a high-volume regional cancer centre in South India
Presenter: Faheem Abdulla
Session: e-Poster Display Session
125P - Analysis of esophageal cancer incidence for last 20 years in Uzbekistan
Presenter: Abrorjon Yusupbekov
Session: e-Poster Display Session
126P - A phase II study of rh-endostatin combined with irinotecan plus cisplatin as the second-line treatment for advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jianhua Chang
Session: e-Poster Display Session
128P - Clinical update with plasma and tumour-based genomic analyses in expansion part of phase I study of selective FGFR inhibitor E7090
Presenter: Chigusa Morizane
Session: e-Poster Display Session
129P - Exploration of the best candidates for splenic hilar lymph node dissection (No.10 LND) based on long-term survival: Stage IIIA proximal gastric cancer may benefit from No.10 LND
Presenter: Zu-Kai Wang
Session: e-Poster Display Session
130P - Reappraisal of the role of no. 10 lymphadenectomy for proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy: A pooled analysis of 4 prospective trials
Presenter: Qing Zhong
Session: e-Poster Display Session
131P - Prognostic value of tumour regression grading (TRG) in patients treated with neoadjuvant chemotherapy plus surgery for gastric cancer
Presenter: Jian-Wei Xie
Session: e-Poster Display Session
132P - Impact of increasing age on cancer- and noncancer-specific mortality in patients with gastric cancer treated by radical surgery: A competing risk analysis
Presenter: Long-Long Cao
Session: e-Poster Display Session
133P - Which patient subgroup needs more attention in early treatment failure? A matched cohort study of treatment failure patterns in locally advanced gastric cancer
Presenter: Dong Wu
Session: e-Poster Display Session